Literature DB >> 32485735

GLP-1 Receptor Agonist as Adjuvant Therapy in Type 1 Diabetes: No Apparent Benefit for Beta-Cell Function or Glycemia.

Maria J Redondo1, Fida Bacha1,2.   

Abstract

Entities:  

Keywords:  GLP-1 receptor agonists; albiglutide; c-peptide; clinical trial; type 1 diabetes; youth

Mesh：

Substances：

Year:  2020        PMID： 32485735      PMCID： PMC7316204          DOI： 10.1210/clinem/dgaa314

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   6.134


× No keyword cloud information.
  8 in total

1.  Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.

Authors:  Nicklas J Johansen; Thomas F Dejgaard; Asger Lund; Camilla Schlüntz; Christian S Frandsen; Julie L Forman; Nicolai J Wewer Albrechtsen; Jens J Holst; Ulrik Pedersen-Bjergaard; Sten Madsbad; Tina Vilsbøll; Henrik U Andersen; Filip K Knop
Journal:  Lancet Diabetes Endocrinol       Date:  2020-03-02       Impact factor: 32.069

2.  Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.

Authors:  Bo Ahrén; Irl B Hirsch; Thomas R Pieber; Chantal Mathieu; Fernando Gómez-Peralta; Troels Krarup Hansen; Areti Philotheou; Sune Birch; Erik Christiansen; Thomas Jon Jensen; John B Buse
Journal:  Diabetes Care       Date:  2016-08-04       Impact factor: 19.112

Review 3.  Glucagon-like peptide 1 in health and disease.

Authors:  Andreas Andersen; Asger Lund; Filip K Knop; Tina Vilsbøll
Journal:  Nat Rev Endocrinol       Date:  2018-07       Impact factor: 43.330

4.  Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.

Authors:  Thomas Fremming Dejgaard; Christian Seerup Frandsen; Tanja Stenbæk Hansen; Thomas Almdal; Søren Urhammer; Ulrik Pedersen-Bjergaard; Tonny Jensen; Andreas Kryger Jensen; Jens Juul Holst; Lise Tarnow; Filip Krag Knop; Sten Madsbad; Henrik Ullits Andersen
Journal:  Lancet Diabetes Endocrinol       Date:  2015-12-03       Impact factor: 32.069

5.  Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks.

Authors:  Nitesh D Kuhadiya; Sandeep Dhindsa; Husam Ghanim; Aditya Mehta; Antoine Makdissi; Manav Batra; Sartaj Sandhu; Jeanne Hejna; Kelly Green; Natalie Bellini; Min Yang; Ajay Chaudhuri; Paresh Dandona
Journal:  Diabetes Care       Date:  2016-04-05       Impact factor: 19.112

6.  Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.

Authors:  Ronnie Aronson; Peter A Gottlieb; Jens S Christiansen; Thomas W Donner; Emanuele Bosi; Bruce W Bode; Paolo Pozzilli
Journal:  Diabetes Care       Date:  2014-07-10       Impact factor: 19.112

7.  Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.

Authors:  Paolo Pozzilli; Emanuele Bosi; Deborah Cirkel; Julia Harris; Nicola Leech; Francisco J Tinahones; Marie-Christine Vantyghem; Georgios Vlasakakis; Anette-Gabriele Ziegler; Salim Janmohamed
Journal:  J Clin Endocrinol Metab       Date:  2020-06-01       Impact factor: 5.958

8.  Impact of C-peptide preservation on metabolic and clinical outcomes in the Diabetes Control and Complications Trial.

Authors:  John M Lachin; Paula McGee; Jerry P Palmer
Journal:  Diabetes       Date:  2013-10-02       Impact factor: 9.461
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.